210 related articles for article (PubMed ID: 33306229)
1. Effect of everolimus-based drug regimens on CMV-specific T-cell functionality after renal transplantation: 12-month ATHENA subcohort-study results.
Hauser IA; Marx S; Sommerer C; Suwelack B; Dragun D; Witzke O; Lehner F; Schiedel C; Porstner M; Thaiss F; Neudörfl C; Falk CS; Nashan B; Sester M
Eur J Immunol; 2021 Apr; 51(4):943-955. PubMed ID: 33306229
[TBL] [Abstract][Full Text] [Related]
2. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
3. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis.
Basso G; Felipe CR; Cristelli MP; Mansur Siliano J; Viana L; Ferreira Brigido AN; Stopa Martins SB; de Castro Lima Santos DW; Aguiar WF; Tedesco-Silva Junior H; Medina-Pestana JO
Transpl Infect Dis; 2018 Aug; 20(4):e12919. PubMed ID: 29797676
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus disease in de novo kidney-transplant recipients: comparison of everolimus-based immunosuppression without prophylaxis with mycophenolic acid-based immunosuppression with prophylaxis.
Manière L; Noble J; Terrec F; Bennani HN; Chevallier E; Janbon B; Germi R; Bugnazet M; Imerzoukene F; Malvezzi P; Rostaing L; Jouve T
Int Urol Nephrol; 2021 Mar; 53(3):591-600. PubMed ID: 33058036
[TBL] [Abstract][Full Text] [Related]
5. The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial.
de Sandes-Freitas TV; Pinheiro PMA; Sales MLMBO; Girão CM; Campos ÉF; Esmeraldo RM
Transpl Int; 2018 Dec; 31(12):1345-1356. PubMed ID: 29969826
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials.
Brennan DC; Legendre C; Patel D; Mange K; Wiland A; McCague K; Shihab FS
Am J Transplant; 2011 Nov; 11(11):2453-62. PubMed ID: 21812923
[TBL] [Abstract][Full Text] [Related]
7. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
Tedesco-Silva H; Felipe C; Ferreira A; Cristelli M; Oliveira N; Sandes-Freitas T; Aguiar W; Campos E; Gerbase-DeLima M; Franco M; Medina-Pestana J
Am J Transplant; 2015 Oct; 15(10):2655-64. PubMed ID: 25988935
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
Traitanon O; Mathew JM; Shetty A; Bontha SV; Maluf DG; El Kassis Y; Park SH; Han J; Ansari MJ; Leventhal JR; Mas V; Gallon L
PLoS One; 2019; 14(5):e0216300. PubMed ID: 31136582
[TBL] [Abstract][Full Text] [Related]
9. Impact of Everolimus and Low-Dose Cyclosporin on Cytomegalovirus Replication and Disease in Pediatric Renal Transplantation.
Höcker B; Zencke S; Pape L; Krupka K; Köster L; Fichtner A; Dello Strologo L; Guzzo I; Topaloglu R; Kranz B; König J; Bald M; Webb NJ; Noyan A; Dursun H; Marks S; Ozcakar ZB; Thiel F; Billing H; Pohl M; Fehrenbach H; Schnitzler P; Bruckner T; Ahlenstiel-Grunow T; Tönshoff B
Am J Transplant; 2016 Mar; 16(3):921-9. PubMed ID: 26613840
[TBL] [Abstract][Full Text] [Related]
10. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.
Radtke J; Dietze N; Spetzler VN; Fischer L; Achilles EG; Li J; Scheidat S; Thaiss F; Nashan B; Koch M
Transpl Infect Dis; 2016 Feb; 18(1):79-88. PubMed ID: 26707694
[TBL] [Abstract][Full Text] [Related]
11. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
12. Viral-specific cytotoxic T-cell responses in HLA-sensitized kidney transplant patients maintained on everolimus and low-dose tacrolimus.
Ge S; Chu M; Tang J; Kahwaji J; Karasyov A; Lovato D; Vo A; Choi J; Jordan SC; Zhang R; Toyoda M
Transpl Infect Dis; 2022 Apr; 24(2):e13805. PubMed ID: 35213773
[TBL] [Abstract][Full Text] [Related]
13. Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study.
Watarai Y; Danguilan R; Casasola C; Chang SS; Ruangkanchanasetr P; Kee T; Wong HS; Kenmochi T; Amante AJ; Shu KH; Ingsathit A; Bernhardt P; Hernandez-Gutierrez MP; Han DJ; Kim MS
Clin Transplant; 2021 Oct; 35(10):e14415. PubMed ID: 34216395
[TBL] [Abstract][Full Text] [Related]
14. Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia.
Belliere J; Kamar N; Mengelle C; Allal A; Sallusto F; Doumerc N; Game X; Congy-Jolivet N; Esposito L; Debiol B; Rostaing L
Transpl Int; 2016 Mar; 29(3):315-22. PubMed ID: 26575959
[TBL] [Abstract][Full Text] [Related]
15. Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus.
Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T
Transplant Proc; 2018 May; 50(4):1050-1055. PubMed ID: 29631750
[TBL] [Abstract][Full Text] [Related]
16. Incidence of cytomegalovirus infection in seropositive kidney transplant recipients treated with everolimus: A randomized, open-label, multicenter phase 4 trial.
Kaminski H; Kamar N; Thaunat O; Bouvier N; Caillard S; Garrigue I; Anglicheau D; Rérolle JP; Le Meur Y; Durrbach A; Bachelet T; Savel H; Coueron R; Visentin J; Del Bello A; Pellegrin I; Déchanet-Merville J; Merville P; Thiébaut R; Couzi L
Am J Transplant; 2022 May; 22(5):1430-1441. PubMed ID: 34990047
[TBL] [Abstract][Full Text] [Related]
17. Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients.
Felipe C; Ferreira A; Bessa A; Abait T; Perez JD; Casarini DE; Medina-Pestana J; Tedesco H
Ther Drug Monit; 2018 Feb; 40(1):52-58. PubMed ID: 29271815
[TBL] [Abstract][Full Text] [Related]
18. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
Pascual J; Berger SP; Witzke O; Tedesco H; Mulgaonkar S; Qazi Y; Chadban S; Oppenheimer F; Sommerer C; Oberbauer R; Watarai Y; Legendre C; Citterio F; Henry M; Srinivas TR; Luo WL; Marti A; Bernhardt P; Vincenti F;
J Am Soc Nephrol; 2018 Jul; 29(7):1979-1991. PubMed ID: 29752413
[No Abstract] [Full Text] [Related]
19. A Head-to-head Comparison of De Novo Sirolimus or Everolimus Plus Reduced-dose Tacrolimus in Kidney Transplant Recipients: A Prospective and Randomized Trial.
Toniato de Rezende Freschi J; Cristelli MP; Viana LA; Ficher KN; Nakamura MR; Proença H; Dreige YC; de Marco R; de Lima MG; Foresto RD; Aguiar WF; Medina-Pestana J; Tedesco-Silva H
Transplantation; 2024 Jan; 108(1):261-275. PubMed ID: 37525373
[TBL] [Abstract][Full Text] [Related]
20. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
Tedesco-Silva H; Felipe CR; Slade A; Schmouder RL; Medina Pestana JO
Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
